# First Line Ovarian Cancer Treatment - Cohort Study

> **NCT01832415** · — · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 500 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01832415
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-02
- **Final completion:** 2016-03
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2016-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01832415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01832415, "First Line Ovarian Cancer Treatment - Cohort Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01832415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*